endpts.com·Jun 12, 2026
Eli Lilly has invested in health tech startup Abridge as it aims to enhance clinical trial recruitment and expand its presence in the life sciences sector.
Eli Lilly's investment in Abridge, a health tech startup expanding into clinical trial recruitment, signifies a strategic move toward leveraging digital platforms to streamline and potentially increase efficiency in trial participant recruitment. This investment underscores the growing importance of digital health solutions in optimizing clinical trial processes, presenting a potential opportunity for further integration of AI and telemedicine technologies in trial management.